blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1846408

EP1846408 - 5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.01.2014
Database last updated on 17.09.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2013/12]
Former [2007/43]For all designated states
JANSSEN PHARMACEUTICA N.V.
Turnhoutseweg 30
2340 Beerse / BE
Inventor(s)01 / FREYNE, Eddy Jean Edgard Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
02 / LACRAMPE, Jean, Fernand, Armand Johnson & Johnson
BP 615
27106 Val de Reuil Cedex / FR
03 / PERERA, Timothy Pietro Suren Janssen Pharmaceutica
Turnhoutseweg 30
B-2340 Beerse / BE
04 / TEN HOLTE, Peter Janssen Pharmaceutica N.V.
Turnhoutseweg 30
B-2340 Beerse / BE
05 / LIGNY, Yannick, Aimé, Eddy Johnson & Johnson
BP 615
27106 Val de Reuil Cedex / FR
06 / LARDEAU, Delphine, Yvonne Raymonde Johnson&Johnson
BP 615
27106 Val de Reuil Cedex / FR
07 / LAVRIJSSEN, Tom Janssen Pharmaceutica N.V.
Turnhoutseweg 30
B-2340 Beerse / BE
 [2013/11]
Former [2007/43]01 / FREYNE, Eddy Jean Edgard Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
02 / LACRAMPE, Jean, Fernand, Armand Johnson & Johnson
BP 615
27106 Val de Reuil Cedex / FR
03 / PERERA, Timothy Pietro Suren Janssen Pharmaceutica
Turnhoutseweg 30
B-2340 Beerse / BE
04 / TEN HOLTE, Peter Janssen Pharmaceutica N.V.
Turnhoutseweg 30
B-2340 Beerse / BE
05 / LIGNY, Yannick Johnson & Johnson
BP 615
27106 Val de Reuil Cedex / FR
06 / LARDEAU, Delphine Johnson & Johnson
BP 615
27106 Val de Reuil Cedex / FR
07 / LAVRIJSSEN, Tom Janssen Pharmaceutica N.V.
Turnhoutseweg 30
B-2340 Beerse / BE
Application number, filing date06700707.009.01.2006
[2007/43]
WO2006EP50097
Priority number, dateEP2005010022214.01.2005         Original published format: EP 05100222
US20050644767P18.01.2005         Original published format: US 644767 P
[2007/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006074985
Date:20.07.2006
Language:EN
[2006/29]
Type: A1 Application with search report 
No.:EP1846408
Date:24.10.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 20.07.2006 takes the place of the publication of the European patent application.
[2007/43]
Type: B1 Patent specification 
No.:EP1846408
Date:20.03.2013
Language:EN
[2013/12]
Search report(s)International search report - published on:EP20.07.2006
ClassificationIPC:C07D473/32, C07D487/04, A61K31/519, A61K31/52, A61P35/00
[2007/43]
CPC:
C07D473/32 (EP,US); A61P35/00 (EP); A61P43/00 (EP);
C07D487/04 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/43]
Extension statesAL14.08.2007
BA14.08.2007
HR14.08.2007
MK14.08.2007
YU14.08.2007
TitleGerman:5-gliedrige annelierte heterocyclische pyrimidine als kinaseinhibitoren[2012/43]
English:5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS[2007/43]
French:COMPOSÉ HÉTÉROCYCLIQUE PYRIMIDINE FUSIONNÉ À CINQ BRANCHES COMME INHIBITEUR DE KINASE[2007/43]
Former [2007/43]5-GLIEDRIGE ANILIERTE HETEROCYCLISCHE PYRIMIDINE ALS KINASEINHIBITOREN
Entry into regional phase14.08.2007National basic fee paid 
14.08.2007Designation fee(s) paid 
14.08.2007Examination fee paid 
Examination procedure14.08.2007Examination requested  [2007/43]
05.09.2008Despatch of a communication from the examining division (Time limit: M06)
17.03.2009Application deemed to be withdrawn, date of legal effect  [2009/38]
28.12.2010Despatch of a communication from the examining division (Time limit: M04)
deletedDeletion: Application deemed to be withdrawn, date of legal effect  [2010/43]
21.04.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2010/43]
23.04.2010Reply to a communication from the examining division
20.04.2011Reply to a communication from the examining division
24.10.2012Communication of intention to grant the patent
06.02.2013Fee for grant paid
06.02.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.09.2008
Opposition(s)02.01.2014No opposition filed within time limit [2014/09]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
01.07.2009Request for further processing filed
01.07.2009Full payment received (date of receipt of payment)
Request granted
23.09.2010Decision despatched
Request for re-establishment of rights:23.04.2010Date of receipt
Fees paidRenewal fee
31.01.2008Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
23.04.2010Renewal fee patent year 05
02.02.2011Renewal fee patent year 06
31.01.2012Renewal fee patent year 07
31.01.2013Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.01.201005   M06   Fee paid on   23.04.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.01.2006
AT20.03.2013
BG20.03.2013
CY20.03.2013
CZ20.03.2013
DK20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
MC20.03.2013
NL20.03.2013
PL20.03.2013
RO20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
TR20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
[2016/33]
Former [2016/32]HU09.01.2006
AT20.03.2013
BG20.03.2013
CY20.03.2013
CZ20.03.2013
DK20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
MC20.03.2013
NL20.03.2013
PL20.03.2013
RO20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2016/24]AT20.03.2013
BG20.03.2013
CY20.03.2013
CZ20.03.2013
DK20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
MC20.03.2013
NL20.03.2013
PL20.03.2013
RO20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2014/38]AT20.03.2013
CY20.03.2013
CZ20.03.2013
DK20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
MC20.03.2013
NL20.03.2013
PL20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2014/09]AT20.03.2013
CY20.03.2013
CZ20.03.2013
DK20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
NL20.03.2013
PL20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2013/52]AT20.03.2013
CY20.03.2013
CZ20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
NL20.03.2013
PL20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2013/50]AT20.03.2013
CZ20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
NL20.03.2013
PL20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2013/49]AT20.03.2013
CZ20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
NL20.03.2013
SE20.03.2013
SI20.03.2013
SK20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2013/48]AT20.03.2013
EE20.03.2013
FI20.03.2013
LT20.03.2013
LV20.03.2013
NL20.03.2013
SE20.03.2013
SI20.03.2013
GR21.06.2013
IS20.07.2013
PT22.07.2013
Former [2013/47]FI20.03.2013
LT20.03.2013
LV20.03.2013
SE20.03.2013
SI20.03.2013
GR21.06.2013
PT22.07.2013
Former [2013/38]FI20.03.2013
LT20.03.2013
LV20.03.2013
SE20.03.2013
SI20.03.2013
GR21.06.2013
Former [2013/37]FI20.03.2013
LT20.03.2013
SE20.03.2013
SI20.03.2013
GR21.06.2013
Former [2013/34]LT20.03.2013
SE20.03.2013
Former [2013/33]LT20.03.2013
Cited inInternational search[Y]WO0149688  (UNIVERSITAIRE INSTELLING ANTWE [BE], et al) [Y] 1-12 * claims 1,14 *;
 [DY]EP1147108  (USTAV EX BOTAN AKADEMIE VED CE [CZ]) [DY] 1-12 * the examples *;
 [Y]WO2004065378  (WARNER LAMBERT CO [US], et al) [Y] 1-12 * examples 1,2,5-11,15,16 *;
 [Y]WO2004094426  (USTAV ORGANICKE CHEMIE A BIOCH [CZ], et al) [Y] 1-12 * page 44, line 30 - page 45, line 2; claim 1 *;
 [Y]US2004248905  (MARKWALDER JAY A [US], et al) [Y] 1-12* paragraph [0001]; claim 1 *
by applicantEP0153976
 EP0961775
 EP1147108
 EP1244668
 EP1507780
 EP1590341
    - MCLAUGHLIN ET AL., DRUG DISCOVERY TODAY., (2003), vol. 8, pages 793 - 802
    - FISHER ET AL., EXPERT OPIN. INVESTIG. DRUGS., (2003), vol. 12, pages 955 - 970
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.